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Abstract
Israel, the UK, the USA, and some other wealthier countries lead in the implementation of COVID-19 vaccine mass
vaccination programmes. Evidence from these countries indicates that their ethnic minorities could be as
disproportionately disadvantaged in COVID-19 vaccines roll-out as they were affected by COVID-19-related serious
illnesses. Their disadvantage is linked to their lower social status and fewer social goods compared with dominant
population groups.
Albeit limited by methodology, early studies attribute lower uptake of COVID-19 amongst ethnic minorities to the
wider determinants of vaccine uptake, hesitancy or lack of vaccine confidence, including lower levels of trust and
greater concerns about vaccine safety. Early sentinel studies are needed in all early adopter countries.
One emerging theme among those of reproductive age in minority communities concerns a worry regarding
COVID-19 vaccine’s potential adverse effect on fertility. Respected professional groups reassure this is not a credible
rationale. Drug and vaccine regulators use understandable, cautious and conditional language in emergency
licencing of new gene-based vaccines. Technical assessments on whether there is any potential genotoxicity or
reproductive toxicity should be more emphatic.
From a public health perspective, sentinel studies should identify such community concerns and act early to
produce convincing explanations and evidence. Local public health workforces need to be diverse, multiskilled, and
able to engage well with minorities and vulnerable groups. The local Directors of Public Health in the UK are based
in each local government area and have a remit and opportunity to stimulate speedy action to increase vaccine
uptake.
During the rapid Pandemic Pace of the vaccines roll-out, extra efforts to minimise uptake variations are likely to
achieve improvements in the next year or two. We expect variations will not disappear however, given that
underlying inequalities persist in less inclusive social systems.
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Background
Globally the race is on in rolling out the vaccine against
COVID 19. The most successful countries in population
vaccination against COVID 19 are Israel, the United
Kingdom (UK), the United Arab Emirates (UAE), the
United States of America (US) and Chile. The emerging
evidence from three of these countries (the UK, US and
Israel) indicates that the uptake of the COVID 19 vac-
cine is lower amongst these countries’ ethnic minorities.
However, the concept of ethnic minorities is often
used as though it refers to a constant state of being and
homogenous group. In the UK, ethnic minorities refer to
all ethnic groups except the White British group, mainly
blacks and Arabs and Asians [1]. Israel’s minorities are
mainly Arabs, and in the USA the largest groups are
African-American, Hispanic/Latino, and Asians with
smaller percentages of indigenous populations such as
American Indians and Alaskan Natives.
Harris (2021) defines “ethnic minority” as “a group of
people who differ in race or colour or national, religious,
or cultural origin from the dominant group, often the
majority population of the country in which they live
[2]“. This definition illustrates that the concept is
context-specific; a person could be a member of the mi-
norities in one context and the dominant group in a dif-
ferent context.
It is indisputable that the ethnic minorities in the
western context were disproportionately affected by
COVID-19-related serious illnesses; it also seems
that their engagement with the vaccination pro-
grammes is low.
However, the representation of ethnic minorities in
the literature and media could erroneously lead to the
belief that there is something innate about them that in-
creases their vulnerability and hesitation to engage with
covid-19 vaccine programmes. The ethnic minority are
socio-demographic and culturally too diverse to share
innate qualities that make them vulnerable to COVID-
19 or vaccine reluctant or hesitant. The main similarities
amongst the ethnic minorities across countries is the so-
cial status ascribed to them by the dominant group in
each country. Generally, such social status reduces their
freedom to fully participate in social goods such as hous-
ing, employment, social services, and healthcare services.
This creates vulnerability to COVID-19-related serious
illnesses, distrust, and lower access and engagement with
vaccination programmes.
This commentary is inspired by the study report of re-
spondents to an internet survey reported by Green, Ab-
dullah, Vered and Nitzan in the Israel Journal of Health
Policy Research [3]. Like most assessments of the inter-
action of COVID-19 and ethnic minorities, Green at al;
offered several helpful insights into why initial COVID-
19 vaccine uptake by Israeli Arab citizens is lower than
by the dominant Jewish group [3]. Consistent with most
such studies, their initial rapid methodologies restricted
it from exploring in-depth how social status ascribed to
minorities creates, perpetuates, and sustains health.
This commentary presents our observations of the UK,
US and Israel’s experiences in rolling out COVID-19
vaccination, exploring seven underlying themes;
1. Early warning signals that vaccine uptake is lower
amongst the minority ethnic groups
2. Determinants of lower uptake by ethnic minorities
3. Need for systematic sentinel alert systems covering
variations in uptake of COVID 19 vaccine
4. How minorities feature in COVID-19 vaccine prior-
ity frameworks
5. Reproductive health and Infertility as a specific
minorities concern
6. Why governments, public health systems, scientists,
academics and regulators need to accept a greater
share of responsibility around reassurance as more
gene-based vaccines become available
7. How the public health workforce can respond
effectively to narrow these gaps over time
Early warning signals that vaccine uptake is low
amongst the minority ethnic groups
Countries with strong public health systems have
achieved some early successes in rolling out and vaccin-
ating their populations. Some of the early examples of
success in rolling out vaccine are Israel, the United
Kingdom (UK) and lately, the United States of America
(US).
However, the emerging evidence from these countries
suggests that ethnic minorities and other vulnerable so-
cial groups may be getting further left behind for various
reasons, including vaccine hesitancy.
Israel has led worldwide in the fast rollout. Recent
analyses clarify factors that influenced Israel’s fast rollout
[4, 5]. The first analysis identified 12 factors that enabled
Israel’s rapid rollout across the 9.3 million population
and attributed Israel’s success to include [4]:
1. pre-existing frameworks for making decisions that
involve public health and other experts in vaccine
advice;
2. the Israel National Immunization Technical
Advisory Group (NITAG);
3. strong systems of electronic population health
registers and patient records,
4. high levels of enrolment in healthplan
organisations.
Glied pointed to the Israeli vaccine programme’s suc-
cess arising from the coherent and well-resourced
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national vaccine strategy, built upon the country’s effect-
ive, resilient healthcare system, that is well versed in
responding to other emergencies [5].
However, the evidence shows that the vaccine’s up-
take was lower amongst the minority groups in Israel
[6]. The highest uptake among persons age 50 or
older (89%) was among non-Orthodox Jews. The up-
take was lower among Israeli Arabs (68%) and Israel’s
ultra-Orthodox Jews (62%) [6]. Furthermore, Caspi
et al. indicated that in Israel, there was a strong cor-
relation between vaccine acceptance and socioeco-
nomic status with lower uptake amongst those with
low socioeconomic status [7]. Based on their research,
they recommended that more vaccination promotion
effort should be directed to socioeconomically disad-
vantaged populations [7].
Similar findings have emerged in the earliest major
UK studies. One of the largest early UK retrospective co-
hort studies; covered an overall 961,580 vaccinated
people within 23.4 million GP registered study popula-
tion [8]. Their analysis showed ‘substantial ethnic diver-
gence in the uptake of vaccine amongst the over 80 age
group living outside care homes’ [8]. It also shows, albeit
to a lesser magnitude, the effects of deprivation indica-
tors. The proportion vaccinated to date was highest
among white people (42.6%), with South Asian 29.5%,
and lowest among black people at 20.5% [8]. Sixteen
more detailed ethnic categories were analysed, and black
ethnicity categories had low rates generally, while Ban-
gladeshi/British Bangladeshi (23.0%) and Pakistani/Brit-
ish Pakistani (22.8%) categories also had the lowest
uptake rates. This is of great public health concern given
that the over age 80, Black and Minority Ethnic (BAME)
groups have highest COVID-19 morbidity/mortality
risks [8]. Further evidence reinforcing such concerns
came from varied sources including government statis-
tics [9], the Royal College of General Practitioners [10],
the Royal Society, the British Academy [11], and the
Royal Society of Public Health [12].
Health service providers’ concerns were also being
raised about lower uptake in NHS healthcare workers
from different BAME backgrounds [13]. Since the
healthcare workers were likely to have equal or better
access to vaccines, the lower uptake appeared to be re-
lated primarily to vaccine hesitancy.
Determinants of lower uptake by ethnic
minorities
The UK Scientific Advisory Group for Emergencies
(SAGE) ethnicity sub-group review in December 2020
looked at factors influencing COVID-19 vaccine uptake
among minority ethnic groups and other minority issues
[14, 15]. Their work was set against historical lower eth-
nic minority uptake in other vaccine programmes,
including those introduced last decade, such as against
Rotavirus in children and Shingles (VZ) in population
over age 70 years [14, 15]. Their reviews identified four
barriers to vaccine uptake:
 Lower trust and confidence in vaccine efficacy and
safety
 Lower perception of risk
 Inconvenience and access barriers, including costs
 Context and socio-demographic variation, including
levels of education.
The study by Green and colleagues challenges the the-
ory that lower perception of infection risk is the main
factor in COVID-19 lower uptake [3]. In their study, the
apparent higher educated and younger Arab females
have higher levels of reluctance. They highlighted that
there was a mismatch with apparently greater confidence
and good uptake in standard vaccine programmes for
children and families by educated Arabs. They confirm
that, in general, the uptake of the COVID-19 vaccine is
higher amongst socially advantaged groups regardless of
ethnicity [3]. Previous studies from South Africa, where
Blacks are the majority, appear to confirm the vital prop-
osition that a group’s socioeconomic status within soci-
ety is more the determinant for vaccine uptake than
ethnicity [16]. This study found that vaccine uptake
among deprived black South Africans was significantly
lower than the least deprived [16].
Need for systematic sentinel alert systems
covering variations in uptake of COVID 19
vaccines
Timely information about the progress of rollout can
guide policymakers and program directors at all levels.
And, of course, sentinel information should be tailored
to local demographics.
In Israel, an immediate challenge was to address the
hesitancy among the educated women in the Arab popu-
lation [3]. In the UK, the Office for National Statistics
reports on variations in vaccination uptake, including
minorities’ concerns about side effects, safety, and pos-
sible long-term effects [17].
In the US, the earliest report of variation in uptake of
COVID 19 amongst the minorities came from CDC, but
had had a large percentage of missing data on ethnicity
or race [18]. The Kaiser Family Foundation’s (KFF)
COVID-19 vaccine dashboard recording early responses
in each State to questions eliciting vaccine hesitancy or
lack of ‘vaccine enthusiasm’ [19]. Concerns emerging in
minority groups include [19]:
 That vaccines may contain the live (coronavirus)
virus
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 That there will be out of pocket expenses, that
vaccine is not free and might require health
coverage documentation, or that personal data
collected could be transferred to other agencies,
 That younger age groups are more hesitant than
older and more likely to wait and see (how events
develop, such as a single-dose vaccine)
 Short-term fears of losing time from work to longer-
term concerns about Infertility.
 That health professionals are held in the highest
regard and with reasonably high regard for public
health agencies. Also, that family, friends, and
religious leaders are relatively higher key influencers
in a sizeable proportion and need to be positively
engaged.
Early insights should allow policymakers and program
directors to address such minority group concerns about
composition of vaccines, extra personal costs or loss of
income from more severe side effects. Vaccination pro-
grammes are mainstream social programmes that every-
body is expected to participate in. Arguably, in societies
where minorities are relegated towards society’s margins,
they may be more reluctant to participate in those main-
stream programmes. Early reports, cited above, could
not attribute underlying causation. Studies on perception
and opinion offer partial insight but do not report on
structural facilitators or barriers to service use. There
was little initial reportage on wider determinants of vac-
cine uptake in relation to social position, power, and
inclusiveness.
How minorities feature in COVID-19 vaccine
priority frameworks
This pandemic has demonstrated both the importance
of developing a prioritised set of vaccine recommenda-
tions and recognising that the recommendations and
their priority may need to change over time. In the UK,
the Joint Committee for Vaccination and Immunisation
(JCVI) initially prioritised vaccine recommendations
based on clinical risk as determined by age, clinical con-
ditions, and health and social care worker status [20]. In
their decision about a list of priorities they considered
ethical issues and evidence - specifically relating to in-
equalities and ethnic minorities [21], but concluded on
balance to proceed as above. As the pandemic pro-
gresses, adjustments are being made on priorities, such
as the inclusion of homeless people and people in deten-
tion settings in March 2021 [22].
Although the initial JCVI recommendations were
based on the above evidence, the pandemic has demon-
strated that other factors should also be considered.
These include an ‘intersectional human rights’ approach
balancing risk and benefits across society [23]. Therefore,
the vaccination programmes should balance preserving
scientific integrity and independence along with ethical
frameworks such as informed consenting adults and
building wider trust and engagement with minorities.
Such debates may be helped by comparative analysis with
recent decisions in other countries, such as the European
Centre for Disease Prevention and Control (ECDC) as-
sessments of NITAGs and country priorities in EU/EEA
states [24]. Broader principles, such as the legitimacy
principle for vaccine prioritisation advocated by WHO,
could be adopted from the beginning, through the earliest
consideration of the long list of potentially vulnerable
socio-demographic groups that they identified [25].
Reproductive health and infertility as a specific
minorities concern
Green and colleagues’ study shows that educated Arab
women respondents raised some concerns about the po-
tential effects of the COVID-19 vaccine on fertility. This
was important for them since they were, on average,
about ten years younger than Jewish respondents [3].
The UK based Association of Reproductive and Clin-
ical Scientists and the British Fertility Society, the Hu-
man Fertilisation and Embryo and Authority, and the
Royal College of Obstetrics and Gynaecology, have is-
sued statements to counteract the misinformation that
COVID-19 vaccines could potentially impact male or fe-
male fertility [26–28].
The British Islamic Medical Association (BIMA) also
provided reassuring information for patients in regard to
infertility concerns, and in BIMA’s case, also on other
myths such as about COVID-19 vaccine containing non-
Halal or alcohol-based constituents [29].
There has been measured and cautionary reassurance
around vaccine safety, as there is ongoing research to es-
tablish with certainty the safety of these vaccines. How-
ever, the modern scientific movement towards Gene-
Based Vaccine technology deserves further consideration.
Why governments, public health systems,
scientists, academics and regulators need to
accept a greater share of responsibility around
reassurance as more gene-based-vaccines become
available
Vaccine hesitancy has proven to be a global concern.
Addressing it will require each country sponsoring a
vaccination program to address this issue for its own
population. Since some lessons about addressing vaccine
hesitancy are likely to be generally applicable, ideally
countries would work together to understand and spread
the best practice [30]. Countries all have some degree of
vaccine mistrust and will need various study methods to
explore their own communities’ concerns and the under-
lying reasons. For instance, a recent analysis of COVID-
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19 anti-vaccination social media content in Poland
highlighted ‘angrier’ versus ‘happier’ arguments and
comments [31]. Concerns expressed around morality, re-
ligion, ideology and personal testimonies about children/
others harmed were angrier, along with comments in-
volving civil liberties, conspiracy/search for truth theor-
ies, and safety and effectiveness concerns.
There is a need to understand better if some rapid
COVID-19 vaccine policy and technical reviews have
built or eroded public trust or vaccine confidence. It has
been contended that India’s government may have been
overly hasty with lack of transparency in India’s vaccine
(Covaxin) licensing arrangements [32].
Normally vaccine licensing relies on the publication of
satisfactory Phase 3 human studies. It appears that in
some countries, such as India and Russia, rollout followed
smaller Phase 2 studies [33–36]. There are concerns about
the potential over-closeness of vaccine regulators and
public health decision-makers to their national govern-
ments that may have influenced vaccine policy.
The continuing metanalysis of studies into COVID-19
during pregnancy shows that women being of non-white
ethnic origin might also be a risk factor for severe covid-
19 infection [37]. This is a strong argument for pre-
conceptual vaccination rather than vaccination in
pregnancy.
There are large numbers of Gene-Based-Vaccine can-
didates under development for COVID-19 [38]. These
advancing technologies are open to mistrust by anti-
science and anti-vaccine advocates. Regulatory and ex-
pert bodies need to take a joined-up approach to com-
municate the best evidence to speedily counter vaccine
non-confidence narratives, as with infertility concerns.
Any ensuing controversy or disagreement among med-
ical, public health and international scientific communi-
ties is a likely media trigger that can help spread
uncertainty worldwide.
All countries must have modern public health risk
communication strategies. In the UK, public health risk
communication advice was first issued in 1997. It was
generated by communication mistakes and harsh lessons
from public health crises of confidence and controver-
sies, such as with the variant Creutzfeldt-Jacob (vCJD)
outbreak from Bovine Spongiform Encephalopathy (BSE)
or ‘mad-cow disease’ infecting beef, Salmonella in UK
egg supplies, and the Mumps, Measles and Rubella
(MMR) vaccine controversy [39]. Bennett, Calman and
co-authors, updated their thinking in 2010 on the social
amplification of risk, and fright factors and media trig-
gers [40]. Six of their eleven fright factors apply to
COVID-19 vaccines, such as genetically engineered vac-
cines and worries about fertility. Fright factors include
concerns about perceived threats to health from un-
familiar sources or that may pose some long-term
danger to pregnant women or future generations or are
subject to contradictory statements from responsible
sources.
Several agencies and expert groups are engaged in with
COVID-19 vaccine rollout within the UK, such as the
JCVI and MRHA (Medicines and Healthcare Products
Regulatory Agency). All perform meaningful and valued
roles but may give scope for inconsistency in the mes-
sage or in emphasis. The UK COVID-19 Vaccine Task
Force has led forcefully on vaccine procurement, sup-
porting vaccine industry development, and supporting
international aid and supplies. However, their 2020 end
of year report made claims for a comprehensive commu-
nication campaign [41]. This is partly accurate but does
not fully acknowledge the challenges in successfully en-
gaging minority groups. Further detailed guidance from
the UK Race Disparities Unit encourages targeted local
action and engagement with support from community
champions and other local leadership [42].
A wider communications challenge is the understand-
ably cautious technical and legal language used in condi-
tional approvals or emergency-use licensing [43–47].
COVID-19 infection places its viral RNA in abundance
within our bodies’ cells. Yet, public hesitancy over using
vaccines to place small segments of this virus’s RNA in
our cells.
Medicines and vaccines regulators should inspire wider
trust and take credit for rapid comprehensive reviews of
vaccine trial studies. However, overly enthusiastic rhetoric
of leaping forward and a revolution in vaccine technology
[48] might reinforce some reluctance. A measured look-
back at lessons from recent Gene-Based-Vaccine uses in
Ebola outbreaks emphasises taking all communities with
you from the start, from experiences with affected indi-
genous African communities [49].
How the public health workforce can respond
effectively to narrow these gaps over time
Rigorous approaches are needed to set up and run suc-
cessful vaccination programmes [50]. Many different
vaccination services needed to be sited across large pop-
ulations in England [51]. Mass COVID-19 vaccine clinic
venues may not suit some ethnic/cultural or faith-based
minority groups where privacy is harder to maintain,
where language difficulties could arise, and the pace of
vaccination leaves little room for meaningful dialogue at
that point, given each vaccine clinical encounter usually
takes only a few minutes. We do not know yet if some
UK venues (e.g. racecourses) or smaller church-related
(Christian) venues have influenced ethnic minorities’
choices. However, some faith-based and ethnic group
communities are now more actively involved in local
and more tailored communications in the UK. There are
efforts to locate vaccination clinics in more accepted
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local assets, such as worship places, including mosques.
A variety of minority language materials are now avail-
able. Local COVID-19 vaccine community champions
and influencers in minority groups are being identified
and encouraged.
A Kaiser Family Foundation recently reported many
local public health and state’s innovative and respon-
sive measures scattered across the USA. All responses
should be evaluated rigorously to learn for future vac-
cine rollout-out and wider public health practice to
reduce health inequalities [52]. Their vaccine COVID-
19 dashboard gathers useful lessons from the USA. It
represents a coordinated well-resourced approach by
a non-statutory research body that actively seeks out
and reports data on public perception and State-level
systems responses early on and by tracking it over
time [52].
The 1997 UK public health risk communication
guidance advised to engage and build trust carefully,
not to overlook basic stakeholder concerns, and to in-
vestigate and communicate in a two-way process
throughout the timescales [37]. Razai and colleagues
more recently advised on the ‘need to engage, listen
with respect, communicate effectively, and offer prac-
tical support to those who have yet to make up their
minds about the vaccine’ [53]. England’s local public
health leadership falls to the Directors of Public
Health (DsPH), who moved from the NHS into local
government systems in 2013. There is hope that local
Directors of Public Health will help in vaccine catch-
up for local minorities, and a light touch national re-
view will shortly look at the range of local activities
after enquiring with DsPH.
Firstly, the pivotal role of DsPH has been better
recognised recently, rather than being marginalised
by central government earlier in the pandemic. Sec-
ondly, DsPH are geographically closer to their popu-
lations (e.g. about 1 DPH per 320,000 in North-West
England’s region of about 7.3 million people, closer
than in Israel where regional public health Directors
cover populations over 1 m people). Thirdly there is
some diversity of gender and ethnicity in that group
of 23 DsPH. Finally, the UK multidisciplinary spe-
cialist public health workforce allows DsPH to repre-
sent differing skillsets. There may need to be a
greater focus on cultural competency skills in the
whole public health workforce in our future curric-
ula and training programmes. Useful tools and mate-
rials have been collated for healthcare professionals
from Public Health England [54] and the NHS Race
and Health Observatory [55]. Guidance from UK
SAGE [14] includes ongoing community engagement,
tailored communication shared by trusted sources,
and avoiding stigmatisation and discrimination.
Conclusions - pandemic pace – the race for better
vaccines continues along with increasing levels of
population vaccination. How far can countries
protect such vulnerable minority groups in the
next year or two?
The race for vaccines goes on with the early pacesetters
showing urgent minority group issues to addressed. Ul-
timately this is also a race between humanity versus the
virus, as it spreads and mutates. For public health pro-
fessionals, our race is between advancing our societies’
organised efforts to promote widest population protec-
tion and equity to achieve universal coverage while bat-
tling the brakes of community hesitancy and systems
disruption.
Pandemic pace implies accelerated emergency devel-
opment of biotechnologies, with an understanding that
‘every day counts’ [56]. Perceptions are prone to change
in communities and need tracking. Distrust, however,
propagated, may take various forms around the world.
In the USA, there is a high current distrust of vaccine
among male Republican Party voters [57]. This is not a
minority ethnic grouping but still needs to be under-
stood, for instance as to whether motivated by political
positioning, or anti-science or male-associated percep-
tions. In a recently published French study conducted
last summer, there is higher mistrust of vaccines made
in China, and, worryingly, 40 (32.2%) out of the 124
healthcare workers responding would make ‘outright re-
fusal’ [58] In Australia, opinion has moved, between Au-
gust 2020 to January 2021, away from vaccine
confidence, notably in females, and in Indigenous Aus-
tralians and those who speak a language other than Eng-
lish in their own homes [59].
The rollout of vaccines against SARS-CoV-2 in several
countries have had differential uptake between the ma-
jority and minority populations. Although there has been
some evidence of vaccine hesitancy and resistance in all
populations within each country, the phenomenon ap-
pears to be greater among the minority populations.
This is particularly unfortunate since these same minor-
ity populations have had higher attack rates of disease
due to SARS-CoV-2 and should benefit more from the
vaccines. It looks possible for localised public health sys-
tems to identify and diminish vaccine hesitancy through
local disease and risk-perception surveillance and by fur-
ther building trust and even closer engagement with eth-
nic and other minorities and by adapting vaccination
services for greater fit with each minority community.
Public health policy measures from the seven themes
above should include:
1. All countries should develop strong vaccine data
systems, to analyse and report uptake data suitable
to their minorities composition. Ethnicity
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terminologies in our countries can be contentious
and global thinking about minorities classification
need to be updated [60].
2. Public health research should focus on the
underlying determinants of disadvantage and
exclusion as well as vaccine perceptions and vaccine
access factors. They should avoid furthering stigma,
blame and further discrimination for excluded
groups and report objectively on structural
determinants and any discriminatory or racist
policies or exclusion.
3. Vaccine programs should promote speedy sentinel
alerting studies, such as with the Israel example [3]
and the others above shown from USA, UK and
other countries. These should complement
responsive routine vaccine surveillance systems.
4. All country-level vaccine prioritising frameworks
should recognise higher infection risk in minorities
and specify strategic goals for high uptake and
equity. Where vaccine certification or passports are
introduced [61], they should show whether they
hinder or promote uptake by minorities. We also
recognise, but do not comment here, that major
vaccine access equity problems for Palestinian pop-
ulations need to be addressed fully in Gaza and
West Bank.
5. Public health professions and scientists should give
coordinated attention to any concerns about
perceptions of potential long-term effects, such as
about reproductive toxicity and Infertility. A danger
is with newer gene-based vaccines, including genet-
ically modified technologies for other target infec-
tions, that wider vaccine distrust could grow, giving
greater energy to modern infodemics or to sources
of active health misinformation and anti-
vaccination proponents.
6. Policymakers should work closely with regulatory
agencies to evaluate both efficacy and safety and
pursue rapid, open scientific publication of evidence
reviews. The pandemic’s emergency vaccine
authorisations have understandable conditionality
and cautious language. Uncertainty or
precautionary messages can be exploited by those
with anti-vaccination motives and encourage
greater ‘hesitancy’ in some social groups. Policy-
makers should update frameworks for assessing vac-
cine efficacy and effectiveness further than recently
proposed [62], to embrace quantitative and qualita-
tive analysis of vaccine perceptions at local commu-
nity and minority group level. Inevitably, as
pandemic vaccines are rolled out fast to millions of
people, there will be rare clinical conditions re-
ported that might be linked to vaccines, such as
clotting disorders [63]. These have the potential to
fuel vaccine hesitancy. However, if policymakers as-
sess and handle these well, they could minimise
hesitancy. They may pause or suspend vaccine use
meanwhile for some of the population or all. Coun-
tries may vary in their historical precautionary
stances on vaccines. Ultimately, vaccination costs
and benefits should always be assessed and dis-
cussed openly.
7. Public health professional systems and institutions
will need to be reviewed with regard to community
engagement. The public health workforces will
probably need to be strengthened in capacity and
capability to identify and respond better to
communicable disease inequalities and variations in
vaccine uptake at the locality level and integrate
enhanced supportive expertise from academic,
clinical and other professional experts. We must
work closely with local GP and other primary care
colleagues who are trusted in their communities
and should be supported in their community-based
commitments and innovations [64].
It is not too late for policymakers to ensure that health
inequalities are not further exacerbated and to learn les-
sons from early mass vaccination programmes [65].
Already in the UK some of these hesitancy gaps are less-
ening [66]. However, vaccine safety concerns about rarer
disorders are to be expected as newer vaccines appear
and large populations are immunised. Strong engage-
ment with minority groups should continue to build
trust. However, greater attention should be given to the
fundamental social and structural determinants of the
distrust of governments and state institutions. Otherwise
it is unlikely that the gaps in uptake will disappear
altogether.
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